Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 2, 1998, Pages 518-526

  Ko, Mei Chuan ^a   Butelman, Eduardo R ^a,b   Traynor, John R ^a   Woods, James H ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ALFENTANIL; BREMAZOCINE; CLOCINNAMOX; DELTA OPIATE RECEPTOR; ENADOLINE; ETHYLKETAZOCINE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALTREXONE; OPIATE AGONIST; RADIOLIGAND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BRAIN MEMBRANE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031809173     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
2. Attali B, Gouarderes C, Mazarguil H, Audiger Y and Cros J (1982) Evidence for multiple "kappa" binding sites by use of opioid peptides in the guinea-pig lumbosacral spinal cord. Neuropeptides 3:53-64.
3. Bertalmio AJ, France CP and Woods JH (1993) Establishing correlations between the pharmacodynamic characteristics of opioid agonists and their behavioral effects, in Opioids II (Herz A, ed) pp 449-469, Springer-Verlag, Berlin.
4. 2 analysis. J Pharmacol Exp Ther 243:591-597.
5. Bodnar R, Paul D and Pasternak GW (1991) Synergistic analgesic interactions between the periaqueductal gray and the locus coeruleus. Brain Res 558:224-230.
6. Broadbear JH, Negus SS, Butelman ER, de Costa BR and Woods JH (1994) Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writhing assay. Psychopharmacology 115:311-319.
7. Burke TF, Woods JH, Lewis JW and Medzihradsky F (1994) Irreversible opioid antagonist, effects of clocinnnmox on opioid analgesia and mu receptor binding in mice. J Pharmacol Exp Ther 271:715-721.
8. 2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J Pharmacol Exp Ther 264:145-151.
9. Butelman ER, Negus SS, Ai Y, de Costa BR and Woods JH (1993b) Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys, J Pharmacol Exp Ther 267:1269-1276.
10. Butelman ER, France CP and Woods JH (1995a) Agonist and antagonist effects of dynorphin A-(1-13) in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 275:374-380.
11. Butelman ER, Winger G, Zernig G and Woods JH (1995b) Butorphanol: Characterization of agonist and antagonist effects in rhesus monkeys. J Pharmacol Exp Ther 272 845-853.
12. Butelman ER, Negus SS, Lewis JW and Woods JH (1996) Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys. Psychopharmacology 123:320-324.
13. Butelman ER, Ko M-C, Sobczyk-Kojiro K, Mosberg HI, Van Bemmel B, Zernig G and Woods JH (in press) Kappa-opioid receptor binding populations in rhesus monkey brain: Relationship to an assay of thermal antinociception. J Pharmacol Exp Ther. (in press).
14. Cheng Y-C and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
15. Clark SJ, Follenfant RL and Smith TW (1988) Evaluation of opioid-induced antinociceptive effects in anaesthetized and conscious animals. Br J Pharmacol 95:275-283.
16. 2 subtype. J. Pharmacol Exp Ther 251:461-468.
17. Comer SD, Burke TF, Lewis JW and Woods JH (1992) Clocinnamox: A novel, systemically-active, irreversible opioid antagonist. J Pharmacol Exp Ther 262: 1051-1056.
18. Craft RM and Dykstra LA (1992) Agonist and antagonist activity of kappa opioids in the squirrel monkeys: II. Effect of chronic morphine treatment. J Pharmacol Exp Ther 260:334-342.
19. Dykstra LA and Woods JH (1986) A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys. J Pharmacol Methods 15:263-269.
20. Dykstra LA, Gmerek DE, Winger G and Woods JH (1987) Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic actions of quadazocine and β-funaltrexamine. J Pharmacol Exp Ther 242:421-427.
21. Dykstra LA and Massie CA (1988) Antagonism of the analgesic effects of mu and kappa opioid agonists in the squirrel monkey. J Pharmacol Exp Ther 246:813-821.
22. Eisenberg RM (1985) The occurrence of cross-tolerance between morphine and ethylketocyclazocine using the tail-flick test: Lack of effect of diazepam, phenobarbital, or amphetamine. Life Sci 37:915-922.
23. Emmerson PJ, Liu M-R, Woods JH and Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637.
24. France CP, Adams JU and Woods JH (1987) Comparison of naltrexone and quaternary naltrexone after systemic and intracerebroventricular administration in pigeons. Neuropharmacology 26:541-548.
25. France CP, de Costa BR, Jacobson AE, Rice KC and Woods JH (1990) Apparent affinity of opioid antagonists in morphine-treated rhesus monkeys discriminating between saline and naltrexone. J Pharmacol Exp Ther 252:600-604.
26. France CP, Medzihradsky F and Woods JH (1994) Comparison of kappa opioids in rhesus monkeys: Behavioral effects and receptor binding affinities. J Pharmacol Exp Ther 268:47-58.
27. Gmerek DE, Cowan A and Woods JH (1986) Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J Pharmacol Exp Ther 236:8-13.
28. Gmerek DE, Dykstra LA and Woods JH (1987) Kappa opioids in rhesus monkeys. III. Dependence associated with chronic administration. J Pharmacol Exp Ther 242:428-436.
29. Hayes AG, Skingle M and Tyers MB (1986) Reversal by β-funaltrexnmine of the antinociceptive effect of opioid agonists in the rat. Br J Pharmacol 88:867-872.
30. Herrero JF and Headley PM (1993) Functional evidence for multiple receptor activation by k-ligands in the inhibition of spinal nociceptive reflexes in the rat. Br J Pharmacol 110:303-309.
31. Horan PJ, de Costa BR, Rice KC and Porreca F (1991) Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: Evidence of kappa opioid receptor multiplicity in mice. J Pharmacol Exp Ther 257:1154-1161.
32. Horan PJ, de Costa BR, Rice K, Haaseth RC, Hruby VJ and Porreca F (1993) Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: Further functional evidence of opioid κ receptor multiplicity in the mouse. J Pharmacol Exp Ther 266:926-933.
33. Horan PJ and Porreca F (1993) Lack of cross-tolerance between U69,593 and bremazocine suggests κ-opioid receptor multiplicity in mice. Eur J Pharmacol 239:93-98.
34. Kim K-W, Eun Y-A, Soh S-M, Eun J-S and Cho K-P (1996) Ligand binding profiles of U-69,593-sensitive and -insensitive sites in human cerebral cortex membranes: Evidence of kappa opioid receptors heterogeneity. Lift Sci 58:1671-1679.
35. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
36. Negus SS, Burke TF, Medzihradsky F and Woods JH (1993) Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: Antagonism by quadazocine. J Pharmacol Exp Ther 267:896-903.
37. Nock B, Giordano AL, Cicero TJ and O'Connor LH (1990) Affinity of drugs and peptides for U-69,593-sensitive and -insensitive kappa opiate binding sites: The U-69,593-insensitive site appears to be the beta endorphin-specific epsilon receptor. J Pharmacol Exp Ther 254:412-419.
38. 3 related opioid receptor. Mol Pharmacol 47:1180-1188.
39. Pasternak GW (1993) Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 18:1-18.
40. Pasternak GW and Standifer KM (1995) Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmacol Sci 16:344-350.
41. Pitts RC and Dykstra LA (1994) Antinociceptive and response rate-altering effects of kappa opioid agonists, spiradoline, enadoline and U69,593, alone and in combination with opioid antagonists in squirrel monkeys. J Pharmacol Exp Ther 271:1501-1508.
42. Porreca F, Cowan A, Raffa RB and Tallarida RJ (1982) Tolerance and cross-tolerance studies with morphine and ethylketocyclazocine. J Pharm Pharmacol 34:666-667.
43. Rossi GC, Leventhal L, Bolan E and Pasternak GW (1997) Pharmacological characterization of orphanin FQ/nociceptin and its fragments. J Pharmacol Exp Ther 282:858-865.
44. Rothman RB, Bykov V, de Costa BR, Jacobson AE, Rice KC and Brady LS (1990) Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides 11:311-331.
45. 2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum. Br J Pharmacol 122:520-524.
46. Simonin F, Gaveriaux-Ruff C, Befort K, Matthes H, Lannes B, Micheletti G, Mattei M-G, Charron G, Bloch B and Kieffer B (1995) κ-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci USA 92:7006-7010.
47. Takemori AE (1974) Determination of pharmacological constants: Use of narcotic antagonists to characterize analgesic receptors, in Advances in Biochemical Psychopharmacology (Braude M, Harris L, May E, Smith J and Villarreal J, eds) vol 8, pp 335-344, Raven Press, New York.
48. 2 and receptor differentiation: A statistical analysis of competitive antagonism. Life Sci 25:637-654.
49. Tallarida RJ and Murray RB (1987) Manual of Pharmacologic Calculations with Computer Programs. Springer-Verlag, New York.
50. Traynor J (1989) Subtypes of the κ-opioid receptor: fact or fiction? Trends Pharmacol Sci 10:52-53.
51. 2 opioid receptors in rat and guinea pig brain. Brain Res 562:57-65.
52. Vivian JA, Van Bemmel B, Lewis JW and Woods JH (1997) Behavioral effects of butorphanol after clocinnamox administration in rhesus monkeys. Presented at the 59th Annual Meeting of the College for Problems on Drug Dependence, Nashville, TN, June 14-19, 1997.
53. Walker EA (1989) Apparent affinity and efficacy estimates for opioids in rhesus monkeys. Doctoral dissertation, University of Michigan.
54. Ward SJ, Portoghese PS and Takemori AE (1982) Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine. J Pharmacol Exp Ther 220:494-498.
55. Wood MS, Rodriguez FD and Traynor JR (1989) Characterisation of kappa-opioid binding sites in rat and guinea-pig spinal cord. Neuropharmacology 28:1041-1046.
56. 3H]diprenorphine binding to kappa-sites in guinea-pig and rat brain: Evidence for apparent heterogeneity. J Neurochim 53:173-178.
57. 2 analysis in assessment of opioid abuse liability. Trends Pharmacol Sci 13:282-285.
58. Zernig G, Butelman ER, Lewis JW, Walker EA and Woods JH (1994) In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J Pharmacol Exp Ther 269:57-65.
59. Zhang W-M, Jin W-Q and Wong TM (1996) Multiplicity of kappa opioid receptor binding in the rat cardiac sarcolemma. J Mol Cell Cardiol 28:1547-1554.
60. Zhu J, Chen C, Xue J-C, Kunapuli S, DeRiel JK and Liu-Chen L-Y (1995) Cloning of a human κ opioid receptor from the brain. Life Sci 56:PL201-PL207.
61. 2 opioid receptors. Proc Natl Acad Sci USA 85:4061-4065.